» Articles » PMID: 37138878

Reprogramming Viral Immune Evasion for a Rational Design of Next-generation Vaccines for RNA Viruses

Overview
Journal Front Immunol
Date 2023 May 4
PMID 37138878
Authors
Affiliations
Soon will be listed here.
Abstract

Type I interferons (IFNs-α/β) are antiviral cytokines that constitute the innate immunity of hosts to fight against viral infections. Recent studies, however, have revealed the pleiotropic functions of IFNs, in addition to their antiviral activities, for the priming of activation and maturation of adaptive immunity. In turn, many viruses have developed various strategies to counteract the IFN response and to evade the host immune system for their benefits. The inefficient innate immunity and delayed adaptive response fail to clear of invading viruses and negatively affect the efficacy of vaccines. A better understanding of evasion strategies will provide opportunities to revert the viral IFN antagonism. Furthermore, IFN antagonism-deficient viruses can be generated by reverse genetics technology. Such viruses can potentially serve as next-generation vaccines that can induce effective and broad-spectrum responses for both innate and adaptive immunities for various pathogens. This review describes the recent advances in developing IFN antagonism-deficient viruses, their immune evasion and attenuated phenotypes in natural host animal species, and future potential as veterinary vaccines.

Citing Articles

The Role of Sustained Type I Interferon Secretion in Chronic HIV Pathogenicity: Implications for Viral Persistence, Immune Activation, and Immunometabolism.

Teer E, Mukonowenzou N, Essop M Viruses. 2025; 17(2).

PMID: 40006894 PMC: 11860620. DOI: 10.3390/v17020139.


The Strategies Used by Animal Viruses to Antagonize Host Antiviral Innate Immunity: New Clues for Developing Live Attenuated Vaccines (LAVs).

Chen N, Zhang B Vaccines (Basel). 2025; 13(1).

PMID: 39852825 PMC: 11768843. DOI: 10.3390/vaccines13010046.


Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection.

Mihaescu G, Chifiriuc M, Filip R, Bleotu C, Ditu L, Constantin M Front Immunol. 2024; 14:1273604.

PMID: 38288121 PMC: 10822962. DOI: 10.3389/fimmu.2023.1273604.


Suppression of TRIM19 by arterivirus nonstructural protein 1 promotes viral replication.

Su C, Hung Y, Tang J, Han M, Everett R, Yoo D Virus Res. 2023; 340:199302.

PMID: 38104946 PMC: 10776440. DOI: 10.1016/j.virusres.2023.199302.

References
1.
Azzinaro P, Medina G, Rai D, Ramirez-Medina E, Spinard E, Rodriguez-Calzada M . Mutation of FMDV L H138 residue drives viral attenuation in cell culture and in swine. Front Vet Sci. 2022; 9:1028077. PMC: 9661595. DOI: 10.3389/fvets.2022.1028077. View

2.
Best S, Morris K, Shannon J, Robertson S, Mitzel D, Park G . Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J Virol. 2005; 79(20):12828-39. PMC: 1235813. DOI: 10.1128/JVI.79.20.12828-12839.2005. View

3.
van Kasteren P, Knaap R, van den Elzen P, Snijder E, Balasuriya U, van den Born E . In vivo assessment of equine arteritis virus vaccine improvement by disabling the deubiquitinase activity of papain-like protease 2. Vet Microbiol. 2015; 178(1-2):132-7. PMC: 7117436. DOI: 10.1016/j.vetmic.2015.04.018. View

4.
Zhang Z, Liu Q, Sun Y, Li J, Liu J, Pan R . Live attenuated coronavirus vaccines deficient in N7-Methyltransferase activity induce both humoral and cellular immune responses in mice. Emerg Microbes Infect. 2021; 10(1):1626-1637. PMC: 8381960. DOI: 10.1080/22221751.2021.1964385. View

5.
Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S . Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol. 2005; 79(9):5414-20. PMC: 1082737. DOI: 10.1128/JVI.79.9.5414-5420.2005. View